The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...

Wells Fargo lowered the firm’s price target on Editas Medicine (EDIT) to $9 from $27 and keeps an Equal Weight rating on the shares. With ...

CEST Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting Mechelen, Belgium, 23 October 2024 ...

United Statescategory Phoenix officers put on leave in probe of violent arrest of disabled Black man 1:36 AM UTC Businesscategory US fines American Airlines record $50 million over treatment of ...

Fast bowler Rosemary Mair and offspinner Leigh Kasperek are out from the squad that won them their maiden T20 World Cup ...

Phuket Immigration officers charged the employer of a Sri Lankan man for illegal employment at a construction site in Wichit. The Sri Lankan national, identified by police as K. Piyaralala, was ...